The use of Idarucizumab for dabigatran reversal in clinical practice: A case series

Pavel Goriacko, Vicken Yaghdjian, Issam Koleilat, Mark Sinnett, Harshal Shukla

Research output: Contribution to journalArticle

7 Scopus citations

Abstract

Purpose: To describe the use of idarucizumab (Praxbind, Boehringer Ingelheim) in routine clinical practice at a large urban academic medical center. Summary: Seven total doses of idarucizumab were administered to six unique patients from October 31, 2015, to October 31, 2016. The reversal agent was used in conjunction with local bleeding control measures, blood product transfusions, and acid-suppressive therapy. In 86% of cases, idarucizumab administration resulted in a successful cessation of bleeding by clinical assessment. Two patients expired due to coexisting conditions. Idarucizumab was administered to patients with normal baseline coagulation tests in 43% of cases. No adverse reactions related to idarucizumab were reported. Conclusions: Idarucizumab administration resulted in successful resolution of bleeding by clinical assessment. The therapy for acute bleeding with use of dabigatran (Pradaxa, Boehringer Ingelheim) remains supportive care, in addition to idarucizumab in cases of severe or uncontrolled bleeding. Development of institution-specific protocols and better guidance for using baseline coagulation tests are needed.

Original languageEnglish (US)
Pages (from-to)699-704
Number of pages6
JournalP and T
Volume42
Issue number11
StatePublished - Nov 1 2017

Keywords

  • Anticoagulants
  • Dabigatran
  • Hemorrhage
  • Idarucizumab
  • Reversal

ASJC Scopus subject areas

  • Pharmacology (medical)

Fingerprint Dive into the research topics of 'The use of Idarucizumab for dabigatran reversal in clinical practice: A case series'. Together they form a unique fingerprint.

  • Cite this

    Goriacko, P., Yaghdjian, V., Koleilat, I., Sinnett, M., & Shukla, H. (2017). The use of Idarucizumab for dabigatran reversal in clinical practice: A case series. P and T, 42(11), 699-704.